Related Experiment Video

Updated: May 27, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

Matilde Murga1, Stefano Campaner2, Andres J Lopez-Contreras1

  • 1Genomic Instability Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Nature Structural & Molecular Biology
|November 29, 2011
PubMed

Insights

Targeting replicative stress pathways, like ATR and CHK1, can selectively eliminate cancer cells. This approach effectively prevented Myc-induced tumors and killed Myc-driven lymphomas in mice, highlighting a potential cancer therapy strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Oncogene activation frequently triggers replicative stress, activating ATR and CHK1 pathways.
  • This stress response is thought to be common in tumors, suggesting therapeutic potential.

Purpose of the Study:

  • To investigate if targeting the replicative stress response can selectively eliminate cancer cells.
  • To evaluate the impact of modulating ATR and CHK1 on cancer development and progression.

Main Methods:

  • Utilized a mouse model of ATR-Seckel syndrome with reduced ATR levels.
  • Administered CHK1 inhibitors to Myc-driven lymphoma models.
  • Compared responses in Myc-induced tumors versus K-Ras(G12V)-driven pancreatic adenocarcinomas.

Main Results:

  • Reduced ATR levels prevented Myc-induced lymphoma and pancreatic tumor development in mice.
  • CHK1 inhibitors demonstrated high efficacy against Myc-driven lymphomas.
  • K-Ras(G12V)-driven pancreatic adenocarcinomas lacked detectable replicative stress and did not respond to CHK1 inhibition.
  • Myc overexpression exacerbated ATR-Seckel syndrome phenotypes.

Conclusions:

  • Targeting ATR and CHK1-dependent replicative stress pathways offers a selective strategy for eliminating Myc-driven cancers.
  • The presence or absence of replicative stress dictates therapeutic response to these inhibitors.
  • Oncogenes can influence the severity of diseases associated with replicative stress.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...